"Neurological manifestations of COVID-19" - guideline of the German society of neurology

Standard

"Neurological manifestations of COVID-19" - guideline of the German society of neurology. / Berlit, Peter; Bösel, Julian; Gahn, Georg; Isenmann, Stefan; Meuth, Sven G; Nolte, Christian H; Pawlitzki, Marc; Rosenow, Felix; Schoser, Benedikt; Thomalla, Götz; Hummel, Thomas.

In: Neurol Res Pract, Vol. 2, 51, 2020.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Berlit, P, Bösel, J, Gahn, G, Isenmann, S, Meuth, SG, Nolte, CH, Pawlitzki, M, Rosenow, F, Schoser, B, Thomalla, G & Hummel, T 2020, '"Neurological manifestations of COVID-19" - guideline of the German society of neurology', Neurol Res Pract, vol. 2, 51. https://doi.org/10.1186/s42466-020-00097-7

APA

Berlit, P., Bösel, J., Gahn, G., Isenmann, S., Meuth, S. G., Nolte, C. H., Pawlitzki, M., Rosenow, F., Schoser, B., Thomalla, G., & Hummel, T. (2020). "Neurological manifestations of COVID-19" - guideline of the German society of neurology. Neurol Res Pract, 2, [51]. https://doi.org/10.1186/s42466-020-00097-7

Vancouver

Bibtex

@article{9cff808d438f4b299fa7581b468824a7,
title = "{"}Neurological manifestations of COVID-19{"} - guideline of the German society of neurology",
abstract = "Infection with the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to a previously unknown clinical picture, which is known as COVID-19 (COrona VIrus Disease-2019) and was first described in the Hubei region of China. The SARS-CoV-2 pandemic has implications for all areas of medicine. It directly and indirectly affects the care of neurological diseases. SARS-CoV-2 infection may be associated with an increased incidence of neurological manifestations such as encephalopathy and encephalomyelitis, ischemic stroke and intracerebral hemorrhage, anosmia and neuromuscular diseases. In October 2020, the German Society of Neurology (DGN, Deutsche Gesellschaft f{\"u}r Neurologie) published the first guideline on the neurological manifestations of the new infection. This S1 guideline provides guidance for the care of patients with SARS-CoV-2 infection regarding neurological manifestations, patients with neurological disease with and without SARS-CoV-2 infection, and for the protection of healthcare workers. This is an abbreviated version of the guideline issued by the German Neurological society and published in the Guideline repository of the AWMF (Working Group of Scientific Medical Societies; Arbeitsgemeinschaft wissenschaftlicher Medizinischer Fachgesellschaften).",
author = "Peter Berlit and Julian B{\"o}sel and Georg Gahn and Stefan Isenmann and Meuth, {Sven G} and Nolte, {Christian H} and Marc Pawlitzki and Felix Rosenow and Benedikt Schoser and G{\"o}tz Thomalla and Thomas Hummel",
note = "{\textcopyright} The Author(s) 2020.",
year = "2020",
doi = "10.1186/s42466-020-00097-7",
language = "English",
volume = "2",
journal = "Neurol Res Pract",
issn = "2524-3489",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - "Neurological manifestations of COVID-19" - guideline of the German society of neurology

AU - Berlit, Peter

AU - Bösel, Julian

AU - Gahn, Georg

AU - Isenmann, Stefan

AU - Meuth, Sven G

AU - Nolte, Christian H

AU - Pawlitzki, Marc

AU - Rosenow, Felix

AU - Schoser, Benedikt

AU - Thomalla, Götz

AU - Hummel, Thomas

N1 - © The Author(s) 2020.

PY - 2020

Y1 - 2020

N2 - Infection with the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to a previously unknown clinical picture, which is known as COVID-19 (COrona VIrus Disease-2019) and was first described in the Hubei region of China. The SARS-CoV-2 pandemic has implications for all areas of medicine. It directly and indirectly affects the care of neurological diseases. SARS-CoV-2 infection may be associated with an increased incidence of neurological manifestations such as encephalopathy and encephalomyelitis, ischemic stroke and intracerebral hemorrhage, anosmia and neuromuscular diseases. In October 2020, the German Society of Neurology (DGN, Deutsche Gesellschaft für Neurologie) published the first guideline on the neurological manifestations of the new infection. This S1 guideline provides guidance for the care of patients with SARS-CoV-2 infection regarding neurological manifestations, patients with neurological disease with and without SARS-CoV-2 infection, and for the protection of healthcare workers. This is an abbreviated version of the guideline issued by the German Neurological society and published in the Guideline repository of the AWMF (Working Group of Scientific Medical Societies; Arbeitsgemeinschaft wissenschaftlicher Medizinischer Fachgesellschaften).

AB - Infection with the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to a previously unknown clinical picture, which is known as COVID-19 (COrona VIrus Disease-2019) and was first described in the Hubei region of China. The SARS-CoV-2 pandemic has implications for all areas of medicine. It directly and indirectly affects the care of neurological diseases. SARS-CoV-2 infection may be associated with an increased incidence of neurological manifestations such as encephalopathy and encephalomyelitis, ischemic stroke and intracerebral hemorrhage, anosmia and neuromuscular diseases. In October 2020, the German Society of Neurology (DGN, Deutsche Gesellschaft für Neurologie) published the first guideline on the neurological manifestations of the new infection. This S1 guideline provides guidance for the care of patients with SARS-CoV-2 infection regarding neurological manifestations, patients with neurological disease with and without SARS-CoV-2 infection, and for the protection of healthcare workers. This is an abbreviated version of the guideline issued by the German Neurological society and published in the Guideline repository of the AWMF (Working Group of Scientific Medical Societies; Arbeitsgemeinschaft wissenschaftlicher Medizinischer Fachgesellschaften).

U2 - 10.1186/s42466-020-00097-7

DO - 10.1186/s42466-020-00097-7

M3 - SCORING: Journal article

C2 - 33283160

VL - 2

JO - Neurol Res Pract

JF - Neurol Res Pract

SN - 2524-3489

M1 - 51

ER -